NCT06484634

Role of Low-Molecular-Weight Heparin in Unexplained Recurrent Pregnancy Loss

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 175 (actual)
• Sponsor: RESnTEC, Institute of Research · Academic / Other
• Sex: Female
• Age: 18 Years – 44 Years
• Healthy volunteers: Not accepted

Summary

Using low-molecular-weight heparin (LMWH), outcomes such as live birth rate and the occurrence of pregnancy complications are some of the variables reported in some studies, with varying degrees of success. The present study aimed to compare the role of LMWH in unexplained recurrent pregnancy loss.

Conditions

• Pregnancy Loss

Interventions

Type	Name	Description
DRUG	Low molecular weight heparin	A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.

Timeline

• Start date: 2023-12-01
• Primary completion: 2024-05-31
• Completion: 2024-05-31
• First posted: 2024-07-03
• Last updated: 2024-07-03

Locations

1 site across 1 country: Pakistan